RxDoctor Payments Data

Sakina Abowath

Medical · South Gate, CANPI 1326287525

Payments from drug & device makers

$7,048in general payments, 2019–2025

Across 283 payments — averaging $24.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$2K
  • Sanofi$2K
  • Incyte Corporation$1K
  • Novartis$566
  • LEO Pharma Inc.$460
  • Pfizer$408
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$6,62194%
  • Education$4276%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,048 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$13,060
Medicare patients
44
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast21$97,642
OpzeluraRuxolitinib Phosphate37$85,160
Ivermectin36$10,422
Tacrolimus27$7,470
Calcipotriene22$7,279
Metronidazole42$4,195
Clobetasol Propionate27$1,143
Ketoconazole38$556
Clindamycin Phosphate11$500
Doxycycline Hyclate16$273
Triamcinolone Acetonide18$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$193$97,64221 claims
Incyte CorporationOpzelura$1,038$85,16037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.

Other medical in South Gate

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →